Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Other Working Capital Changes (2016 - 2025)

Cytosorbents (CTSO) has disclosed Other Working Capital Changes for 14 consecutive years, with $187177.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Other Working Capital Changes fell 40.06% year-over-year to $187177.0, compared with a TTM value of $187177.0 through Jun 2025, up 116.11%, and an annual FY2024 reading of $797209.0, up 70.59% over the prior year.
  • Other Working Capital Changes was $187177.0 for Q2 2025 at Cytosorbents, up from -$257931.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $1.6 million in Q4 2022 and bottomed at -$1.5 million in Q3 2022.
  • Average Other Working Capital Changes over 5 years is -$28242.1, with a median of $56636.0 recorded in 2021.
  • Peak annual rise in Other Working Capital Changes hit 483.0% in 2022, while the deepest fall reached 2972.75% in 2022.
  • Year by year, Other Working Capital Changes stood at -$417688.0 in 2021, then skyrocketed by 483.0% to $1.6 million in 2022, then tumbled by 83.35% to $266343.0 in 2023, then skyrocketed by 199.32% to $797209.0 in 2024, then plummeted by 76.52% to $187177.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for CTSO at $187177.0 in Q2 2025, -$257931.0 in Q1 2025, and $797209.0 in Q4 2024.